Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 72.1
Key Takeaways
Risk factor
Strong & resilient to price shocks
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable price performance
Data is available to registered users only
Data is available to registered users only
About
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and commercialization insulin analogues primarily in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro; Raplin, an insulin aspart injection; Raplin 30, an insulin aspart 30 injection; and Similin 30, an insulin...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EB
Data is available to registered users only
